In this continuation of my last article, we will explore these challenges, the opportunities they present and the future ...

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human ...

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD) ...

Adam Steensberg leads Zealand Pharma, a Danish drug maker whose stock has risen by more than 800 per cent since he took over ...

Antibiotic resistance is a global public health threat. Modern health systems rely on antibiotics to prevent and treat ...

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

This is the latest in a string of tie-ups by Anglo-Swedish drugmaker AstraZeneca to use artificial intelligence for drug ...

Eradivir $10.25M Series A funding round Two Eradivir employees conduct research on the company’s EV25 influenza therapeutic.

It will be called PHOENICS FLY and get underway as patients in the first phase 3 study are followed in a long-term open-label study. If it makes it to market, the drug could provide a much-needed ...